Showing 1 - 10 of 35
Regulatory compliance in unprecedented times: how to adapt but stay on track - a guide for the European life sciences industry
The COVID-19 pandemic has had an unprecedented impact on stakeholders in the UK and EU’s life sciences industry - from companies, to third parties, governments, regulators and insurers.
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
This country-specific Q&A provides an overview of product liability laws and regulations applicable in United Kingdom.
The outcome of two Canadian product class actions in 2020 signal hurdles claimants may face around the globe in 2021 in alleging adverse health effects in mass tort claims involving products for consumption such as medical cannabis, other pharmaceutical products and food.
This report examines the key features of the Directive of the European Parliament and of the European Council on representative actions for the protection of the collective interests of consumers and its wider impact on consumer-led litigation across Europe, including comparative insights into national class action mechanisms in the United Kingdom, Belgium, Denmark, France, Portugal, Spain and Ireland.
Despite welcome news of several viable vaccines in production, having been approved for emergency use globally, the race to develop protections against and treatments for COVID-19 is far from over. Alongside the approved vaccines, there are more than 250 potential vaccines at various stages of development. These vaccines will require worldwide roll out in order to contain and protect against the continued spread of COVID-19.
Case review 15/12/2020
Further to our previous update, on 11 December 2020, the Supreme Court dismissed Mastercard’s appeal against Walter Merricks. This landmark decision takes us a step closer to the granting of what would be the largest group action in the history of England and Wales.
In this Q&A, Jenny Yu, the Industry Practice Leader for Chemicals and Life Sciences in the UK at Marsh & McLennan shares her thoughts on the impact of COVID-19 on the life sciences sector.
Case review 13/07/2020
Product liability and the CPA: failure to consider product risks and benefits is all risk and no benefit
On 3 July 2020, Lambert J handed down judgment in the long standing Seroxat group litigation, Bailey and others v GlaxoSmithKline.
On Monday 22 June 2020, the European Parliament and the European Council reached agreement on draft legislation that will introduce a standardised ‘collective action’ regime empowering qualified representative entities to bring collective actions and seek redress on behalf of groups of EU consumers in respect of infringements of EU law.